Research Article | Chemistry | Volume : 10 | Issue : 07 | July 2025 | e-ISSN : 2456-5040

THE USE OF SARACA ASOCA (ASHOKA) BARK AS A RELIEF AGENT FOR MENSTRUAL PAIN: A PHYTOCHEMICAL AND PHARMACOLOGICAL REVIEW

Akhilesh Singh

Department of Chemistry, K S Saket PG College, Ayodhya, UP, India

ABSTRACT

Primary dysmenorrhea, or painful menstruation, is a widespread condition driven by excessive uterine prostaglandin production. While non-steroidal anti-inflammatory drugs (NSAIDs) are the standard treatment, their efficacy is not universal, and they carry a risk of adverse effects, prompting interest in phytotherapeutic alternatives. *Saraca asoca* (Roxb.) De Wilde, the Ashoka tree, is revered in Ayurvedic medicine as a principal remedy for gynecological disorders.

Chemical analysis reveals a rich profile of bioactive compounds, including flavonoids (catechin, epicatechin), tannins, saponins, sterols (β-sitosterol), and specific flavanol glycosides. These constituents underpin a multi-target pharmacological profile, including analgesic and anti-inflammatory effects mediated through the inhibition of cyclooxygenase (COX) and lipoxygenase (LOX) pathways, a proposed uterine-modulating (antispasmodic and tonic) action, and hormonal-balancing properties demonstrated in preclinical models. This paper concludes that while substantial preclinical evidence supports the traditional use of S. *asoca* bark for menstrual pain, its transition to an evidence-based therapeutic is contingent upon addressing critical research gaps, including the need for standardized botanical materials and rigorous, single-herb, placebo-controlled clinical trials.

1. INTRODUCTION

1.1. The Pathophysiology and Burden of Primary Dysmenorrhea

Primary dysmenorrhea is defined as cramping pain in the lower abdomen occurring before or during menstruation, in the absence of any discernible pelvic pathology. It is a highly prevalent gynecological complaint, affecting a substantial percentage of women of reproductive age worldwide and representing a significant cause of recurrent short-term absenteeism from school and work, thereby diminishing overall quality of life.

The underlying pathophysiology is well-established and hormonally driven. The menstrual cycle is initiated by a sharp decline in circulating progesterone levels. This hormonal shift destabilizes endometrial lysosomes, triggering the release of lytic enzymes, including phospholipase A2. This enzyme acts on the phospholipids of endometrial cell membranes, liberating arachidonic acid. The arachidonic acid then serves as a substrate for the cyclooxygenase (COX) enzymes, COX-1 and COX-2, which catalyze its conversion into various prostaglandins (PGs), prostacyclins, and thromboxanes. Women with primary dysmenorrhea have been shown to have significantly elevated levels of these prostaglandins, particularly prostaglandin F2α (PGF_{2\alpha}), in their menstrual fluid compared to eumenorrheic women.

1.2. Therapeutic Landscape: Conventional and Phytotherapeutic Approaches

The cornerstone of conventional therapy for primary dysmenorrhea is the use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and mefenamic acid. The mechanism of action of NSAIDs directly targets the pathophysiology of the condition: they are potent inhibitors of the COX-1 and COX-2 enzymes. By blocking this enzymatic step, NSAIDs effectively prevent the synthesis of prostaglandins from arachidonic acid, which in turn reduces intrauterine pressure, alleviates uterine hypercontractility, and mitigates pain.

Despite their widespread use and proven efficacy, NSAIDs are not a panacea. A notable failure rate of 20-25% has been reported, wherein women experience minimal or no relief.

Within this context, *Saraca asoca* emerges as a preeminent herb in traditional systems of medicine, especially Ayurveda, where it is revered for its profound benefits on female reproductive health and has been used for centuries to manage a range of gynecological and menstrual disorders.

2. PHYTOCHEMICAL PROFILE OF *SARACA ASOCA* BARK

2.1. Major Classes of Bioactive Compounds

The therapeutic efficacy of *Saraca asoca* bark is attributed to its exceptionally rich and complex phytochemical composition. Extensive chemical screening has consistently identified several major classes of bioactive compounds that are responsible for its diverse pharmacological activities. The primary categories reported across numerous studies include flavonoids, tannins, saponins, glycosides, sterols, and alkaloids. The bark is also a source of other phenolic compounds and organic calcium compounds, which contribute to its overall medicinal profile. The presence of these constituents forms the scientific basis for the bark's traditional applications. For example, the high concentration of tannins underpins its astringent properties, which are valuable in treating menorrhagia (heavy bleeding), while the flavonoids are largely responsible for its potent anti-inflammatory and antioxidant effects.

2.2. Characterization of Key Bioactive Molecules

Modern analytical techniques, including High-Performance Thin-Layer Chromatography (HPTLC) and High-Performance Liquid Chromatography (HPLC), have enabled the isolation and precise identification of specific molecules within these broader classes, providing a deeper understanding of the bark's drug properties.

- **Flavanols and Proanthocyanidins:** The bark is particularly abundant in flavan-3-ols, commonly known as catechins. Key molecules identified include (+)-catechin, (-)-epicatechin, and their polymers, such as procyanidin B2. Leucocyanidin, a precursor to anthocyanidins, is also a significant component. These compounds are well-known for their powerful antioxidant capabilities and are strongly linked to the anti-inflammatory action of the bark.
- **Flavanol Glycosides:** Recent investigations have led to the discovery of novel flavanol glycosides with demonstrated anti-inflammatory activity. Compounds such as 3'-deoxyepicatechin-3-O-β-D-glucopyranoside and 3'-deoxycatechin-3-O-α-L-rhamnopyranoside, isolated from a methanol extract, were shown to inhibit the pro-inflammatory cytokine TNF-α, further cementing the bark's role as an inflammation modulator.
- **Sterols:** β-sitosterol is the most prominent phytosterol identified in the bark, as well as in the leaves and stem of the plant. This compound is recognized for a wide range of biological activities, including anti-inflammatory, antioxidant, hypolipidemic, and immunomodulatory properties.
- **Phenolic Acids:** The bark contains important polyphenolic acids, notably gallic acid and ellagic acid. These compounds are major contributors to the extract's strong antioxidant and free-radical scavenging capacity.
- **Phytoestrogens:** Several compounds within the bark have been identified as phytoestrogens, molecules that can exert estrogen-like or anti-estrogenic effects in the body. Quantitative analysis of extracts has confirmed the presence of quercetin, kaempferol, β-sitosterol, and luteolin. The presence of this specific class of compounds provides a strong scientific rationale for the traditional use of *S. asoca* in managing hormonal disorders.

3. PHARMACOLOGICAL MECHANISMS FOR MENSTRUAL PAIN RELIEF

The rich phytochemistry of *Saraca asoca* bark translates into a multifaceted pharmacological profile that offers several plausible mechanisms for alleviating menstrual pain, extending beyond the single-target action of conventional NSAIDs.

3.1. Anti-inflammatory and Analgesic Actions

Preclinical studies have robustly demonstrated the pain-relieving and anti-inflammatory properties of *S. asoca* extracts. In standard animal models of pain, such as the tail-flick test, hot plate test, and acetic acid-induced writhing test, aqueous and alcoholic extracts of the bark and leaves have shown significant analgesic activity, comparable to standard drugs. The anti-inflammatory effects have been similarly validated in the carrageenan-induced paw edema model in rats, where both ethanolic and methanolic extracts caused a significant dose-dependent reduction in inflammation.

The primary mechanism underlying these effects is the inhibition of key inflammatory pathways. Research indicates that the phytochemical constituents of *S. asoca* inhibit the activity of both cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. This dual inhibition is a crucial point of distinction from NSAIDs. While both NSAIDs and *S. asoca* inhibit the COX pathway, thereby blocking the production of pain- and inflammation-inducing prostaglandins, *S. asoca* also appears to inhibit the LOX pathway. The LOX pathway is responsible for the synthesis of leukotrienes, another class of inflammatory mediators that are implicated in dysmenorrhea but are not targeted by conventional NSAIDs. This suggests that *S. asoca* may offer a broader anti-inflammatory action. Furthermore, specific compounds isolated from the bark, such as flavanol glycosides, have been shown to directly inhibit the production of tumor necrosis factor-alpha (TNF-α), a potent pro-inflammatory cytokine.

3.2. Uterine Tonic and Antispasmodic Properties

The effect of *S. asoca* on uterine tissue is complex, with literature containing seemingly contradictory reports of both stimulatory and relaxant properties. Several studies describe the bark extract as having uterotonic, oxytocic, or spasmogenic effects, meaning it stimulates uterine muscle contractions. One investigation noted that this stimulant effect was more pronounced in uteri that were primed with estrogen or in a gravid state. Another important study found that a hot water extract stimulated the uterus in a manner similar to the drug ergot but, crucially, did so without producing the sustained, tonic contractions characteristic of ergot, instead making contractions more frequent and prolonged.

Conversely, a large body of literature, particularly that which discusses its use in the polyherbal formulation Ashokarishta, describes the herb as possessing potent antispasmodic properties. This muscle-relaxing action is essential for relieving the painful, cramping uterine contractions that define dysmenorrhea. The saponins present in the bark are often credited with improving uterine "tone" and contractility.

These conflicting reports may not be mutually exclusive. Rather than being a simple stimulant or relaxant, *S. asoca* may function as a uterine *modulator* or *normalizer*. This hypothesis suggests a dual action: it could strengthen and improve the tone of a weak or atonic uterus (an effect beneficial in postpartum recovery or uterine debility) while simultaneously calming the disorganized, spastic, and painful contractions characteristic of primary dysmenorrhea. Such a normalizing action would reconcile the disparate findings in the literature and explain the herb's broad therapeutic application across a range of uterine disorders. This nuanced mechanism is far more sophisticated than that of a simple antispasmodic and represents a key area for future pharmacological investigation.

3.3. Hormonal Modulation and Its Implications

Building on the phytochemical evidence of its phytoestrogen content, functional studies have provided strong evidence of

the bark's ability to modulate the endocrine system. A key study using an ovariectomized rat model demonstrated that an ethanolic extract of *S. asoca* flowers possessed significant estrogenic potential. The treatment led to a notable increase in uterine weight and uterine glycogen content, effects that were attributed to its phytoestrogen constituents like quercetin and kaempferol.

In a different but highly relevant context, studies on a letrozole-induced rat model of Polycystic Ovary Syndrome (PCOS)—a condition often associated with hormonal imbalance and menstrual irregularities—showed that *S. asoca* extract exerted a normalizing effect. It significantly lowered the elevated serum levels of testosterone and luteinizing hormone (LH) while simultaneously increasing the levels of follicle-stimulating hormone (FSH), estradiol, and progesterone. This demonstrates a sophisticated ability to modulate the entire hypothalamic-pituitary-ovarian (HPO) axis, rather than simply mimicking estrogen. This hormonal balancing action provides a strong mechanistic basis for its traditional use in regulating the menstrual cycle and improving fertility, which can indirectly contribute to the alleviation of cycle-related pain and discomfort.

Feature/ Mechanism	Saraca asoca Bark Extract	Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Primary Target(s)	Multi-target: Inflammatory enzymes, uterine muscle, endocrine system	Specific target: COX-1 & COX-2 enzymes
Effect on Prostaglandins	Inhibition via COX-1 and COX-2 blockade	Potent inhibition via COX-1 and COX-2 blockade
Effect on Leukotrienes	Inhibition via LOX pathway blockade (putative)	No direct effect
Effect on Uterine Contractility	Modulatory: Antispasmodic effect on dysmenorrheic contractions; tonic effect on atonic uterus	No direct effect on uterine muscle; effect is secondary to PG inhibition
Hormonal Effects	Modulates HPO axis; estrogenic/anti-estrogenic activity	No direct hormonal effects
Onset of Action	Likely slower, cumulative effect over time	Rapid onset of action for acute pain relief

Table 1: Comparison of Pharmacological Mechanisms: Saraca asoca Bark Extract vs. Non-Steroidal Anti-inflammatory Drugs (NSAIDs) for Dysmenorrhea

4. CRITICAL REVIEW OF HUMAN STUDIES

Despite a strong foundation of traditional use and preclinical evidence, the clinical validation of *Saraca asoca* as a standalone treatment for primary dysmenorrhea is markedly deficient. A review of major clinical trial registries, such as ClinicalTrials.gov, reveals a lack of registered, high-quality, randomized, double-blind, placebo-controlled trials specifically investigating a single-herb *S. asoca* extract for this indication.

The limited human data that do exist are almost exclusively focused on the complex polyherbal Ayurvedic formulation, Ashokarishta, in which *S. asoca* is the primary but not the sole ingredient. One single-blind, placebo-controlled clinical trial evaluated Ashokarishta for both dysmenorrhea and menorrhagia. While the study reported some positive outcomes in the treatment groups, such as an increase in hemoglobin levels and a decrease in blood clotting time, the study's design and reporting methods have significant limitations that temper the strength of its conclusions. Another study assessing Ashokarishta syrup for primary dysmenorrhea utilized a single-group, pre-post interventional design with a small sample size of 30 patients. Although it reported subjective improvements in pain, nausea, headache, and irritability, this methodology is inherently weak due to the lack of a control group, making it impossible to rule out placebo effects or other confounding variables.

This reliance on data from polyherbal formulations presents a major confounding factor. Ashokarishta contains numerous other herbs, including Musta (*Cyperus rotundus*), Haritaki (*Terminalia chebula*), and Vasa (*Adhatoda vasica*), many of which possess their own independent anti-inflammatory, analgesic, and antispasmodic properties. Therefore, it is scientifically unsound to attribute the clinical effects observed in these trials solely to the action of *Saraca asoca*. The therapeutic benefits could arise from one of the other botanical ingredients or from a synergistic interaction among them.

5. DISCUSSION AND FUTURE DIRECTIONS

5.1. Synthesizing the Evidence: From Tradition to Plausible Mechanism

The enduring legacy of *Saraca asoca* in Ayurveda as a "friend of women" is more than mere folklore; it is increasingly substantiated by a compelling body of scientific evidence. The bark's rich and complex phytochemical profile, detailed in Section 2, provides a strong foundation for its therapeutic claims. The presence of key compounds like flavonoids, tannins, saponins, and sterols underpins a multi-pronged pharmacological mechanism for managing dysmenorrhea that appears more holistic than that of single-target NSAIDs.

The evidence points toward a synergistic combination of effects: a potent anti-inflammatory action through dual COX and LOX inhibition, direct analgesic properties, a unique uterine-modulating capacity that appears to be both antispasmodic and tonic, and a sophisticated hormonal-balancing effect on the HPO axis.

5.2. Identifying Critical Research Gaps Despite its promise, the transition of *S. asoca* from a traditional remedy to a globally accepted, evidence-based clinical option is severely hindered by significant gaps in the existing research. A clear and strategic research roadmap is necessary to address these limitations.

- **Gap 1: Botanical Authentication and Standardization.** The pervasive issue of adulteration with species like *Polyalthia longifolia* and *Kingiodendron pinnatum* renders much of the available data from commercial products and some studies unreliable.
- **Gap 2: Lack of Rigorous Clinical Trials.** The current human evidence for dysmenorrhea is almost entirely indirect, relying on methodologically weak trials of polyherbal formulations.

- **Gap 3: Comparative Efficacy.** There are no clinical trials directly comparing *S. asoca* to the current standard of care for dysmenorrhea.
- **Gap 4: Mechanistic Ambiguity.** The precise nature of the bark's effect on the uterus (the "uterine normalizer" hypothesis) and its hormonal actions (estrogenic vs. anti-estrogenic in different contexts) remains speculative.

CONCLUSION :

Saraca asoca bark stands out as a highly promising phytotherapeutic agent for the management of menstrual pain. Its revered status in traditional medicine is strongly supported by a compelling body of preclinical evidence that demonstrates a multifaceted pharmacological profile. This profile, encompassing anti-inflammatory, analgesic, uterine-modulating, and hormonal-balancing actions, is mechanistically plausible and suggests a potentially more holistic therapeutic approach than conventional NSAIDs. However, the progression of *S. asoca* from a traditional remedy to a component of evidence-based clinical practice is critically impeded by a profound lack of rigorous, single-herb human trials and the pervasive, confounding problem of botanical adulteration. The future of *S. asoca* as a validated therapeutic option for dysmenorrhea depends entirely on the scientific community's commitment to addressing these significant research gaps through well-designed clinical and mechanistic studies that utilize standardized, authenticated botanical materials.

REFERENCES

1. Inflammatory Markers in Dysmenorrhea and Therapeutic Options - MDPI, https://www.mdpi.com/1660-4601/17/4/1191 2. (PDF) Assessment of the efficacy of Ashokarista syrup for the ..., https://www.researchgate.net/publication/383770216_Assessment_of_the_efficacy_of_Ashokarista_syrup_for_the_treatment_of_primary_dysmenorrhea
2. NSAID resistance in dysmenorrhea: epidemiology, causes, and treatment - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC5839921/
3. (PDF) Comparison of herbal medicines and pain relief medications in the treatment of primary dysmenorrhoea among female medical students at Taibah University - ResearchGate, https://www.researchgate.net/publication/365352258_Comparison_of_herbal_medicines_and_pain_relief_medications_in_the_treatment_of_primary_dysmenorrhoea_among_female_medical_students_at_Taibah_University
4. Dysmenorrhea | GLOWM, https://www.glowm.com/section-view/heading/Dysmenorrhea/item/9
5. NSAIDs: Is newer better for dysmenorrhea?, https://cdn.mdedge.com/files/s3fs-public/Document/September-2017/1407OBGM_Article4.pdf
6. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC6953236/
7. emedicine.medscape.com, https://emedicine.medscape.com/article/253812-treatment#:~:text=NSAIDs%20are%20the%20most%20common,PGF2%CE%B1)%20levels%20in%20menstrual%20fluid.
8. Dysmenorrhea, a narrative review of therapeutic options | JPR - Dove Medical Press, https://www.dovepress.com/dysmenorrhea-a-narrative-review-of-therapeutic-options-peer-reviewed-fulltext-article-JPR
9. The Management of Primary Dysmenorrhea - U.S. Pharmacist, https://www.uspharmacist.com/article/the-management-of-primary-dysmenorrhea-43009
10. Effect of Medicinal Herbs on Primary Dysmenorrhoea- a Systematic Review - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC4177637/
11. Menstrual Pain | Cochrane Complementary Medicine, https://cam.cochrane.org/menstrual-pain
12. Comparison of effects of ginger, mefenamic acid, and ibuprofen on pain in women with primary dysmenorrhea - PubMed, https://pubmed.ncbi.nlm.nih.gov/19216660/ 14. Menstrual Cramp Home Remedies to Manage Pain - Healthline, https://www.healthline.com/health/womens-health/menstrual-cramp-remedies
13. Can Herbs Relieve Menstrual Cramps? - American Association of Naturopathic Physicians, https://naturopathic.org/news/622068/Can-Herbs-Relieve-Menstrual-Cramps.htm
14. Exploring Saraca Asoca: Importance, Controversy, and Its Botanical ..., https://www.ijraset.com/research-paper/exploring-saraca-asoca-importance-controversy
15. (PDF)Asoka:HerbalBoontoGynecologicalProblemsAnOverview ..., https://www.researchgate.net/publication/318041805_Asoka_Herbal_Boon_to_Gynecological_Problems_An_Overview_of_Current_Research